High sensitivity flow cytometry immunophenotyping increases the diagnostic yield of malignant pleural effusions.
EpCAM
Flow cytometry
Immunophenotype
Lymphoma
Malignant pleural effusions
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
02
05
2023
accepted:
21
09
2023
medline:
2
11
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Diagnosing malignant pleural effusions (MPE) is challenging when patients lack a history of cancer and cytopathology does not detect malignant cells in pleural effusions (PE). We investigated whether a systematic analysis of PE by flow cytometry immunophenotyping (FCI) had any impact on the diagnostic yield of MPE. Over 7 years, 570 samples from patients with clinical suspicion of MPE were submitted for the FCI study. To screen for epithelial malignancies, a 3-color FCI high sensitivity assay was used. The FCI results, qualified as "malignant" (FCI+) or "non-malignant" (FCI-), were compared to integrated definitive diagnosis established by clinicians based on all available information. MPE was finally diagnosed in 182 samples and FCI detected 141/182 (77.5%). Morphology further confirmed FCI findings by cytopathology detection of malignant cells in PE (n = 91) or histopathology (n = 29). Imaging tests and clinical history supported the diagnosis in the remaining samples. The median percentage of malignant cells was 6.5% for lymphoma and 0.23% for MPE secondary to epithelial cell malignancies. FCI identified a significantly lower percentage of EpCAM
Identifiants
pubmed: 37812366
doi: 10.1007/s10585-023-10236-4
pii: 10.1007/s10585-023-10236-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-515Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Arnold DT, Fonseka D, De, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA (2018) Investigating unilateral pleural effusions: the role of cytology. Eur Respir J 52:1–9. https://doi.org/10.1183/13993003.01254-2018
doi: 10.1183/13993003.01254-2018
Zhang M, Yan L, Lippi G, Hu Z, De (2021) Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review. Translational Lung Cancer Research 10:1557–1570. https://doi.org/10.21037/tlcr-20-1111
doi: 10.21037/tlcr-20-1111
pubmed: 33889529
pmcid: 8044497
Dixon G, Bhatnagar R, Zahan-Evans N, Clive AO, Virgo PF, Brett MT, Otton SH, Medford ARL, Maskell NA (2018) A prospective study to evaluate a diagnostic algorithm for the use of fluid lymphocyte subset analysis in undiagnosed unilateral pleural effusions. Respiration 95:98–105. https://doi.org/10.1159/000481290
doi: 10.1159/000481290
pubmed: 29131120
Chang A, Benda PM, Wood BL, Kussick SJ (2003) Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry. Am J Clin Pathol 119:643–655. https://doi.org/10.1309/FU3FDKYN8AU0891N
doi: 10.1309/FU3FDKYN8AU0891N
pubmed: 12760282
Acosta M, Pereira J, Arroz M (2016) Screening of carcinoma metastasis by flow cytometry: a study of 238 cases. Cytometry part B -. Clin Cytometry 90:289–294. https://doi.org/10.1002/cyto.b.21258
doi: 10.1002/cyto.b.21258
pubmed: 26054018
Wong-Arteta J, Rey M, Aragón L, Gil-Rodríguez E, Bujanda L (2020) The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms. Cytometry part B -. Clin Cytometry 98:504–515. https://doi.org/10.1002/cyto.b.21886
doi: 10.1002/cyto.b.21886
pubmed: 32506689
Pillai V, Cibas ES, Dorfman DM (2013) A simplified flow cytometric immunophenotyping procedure for the diagnosis of effusions caused by epithelial malignancies. Am J Clin Pathol 139:672–681. https://doi.org/10.1309/AJCP4HIFSHMO9WTK
doi: 10.1309/AJCP4HIFSHMO9WTK
pubmed: 23596119
Kentrou NA, Tsagarakis NJ, Tzanetou K, Damala M, Papadimitriou KA, Skoumi D, Stratigaki A, Anagnostopoulos NI, Malamou-Lada E, Athanassiadou P, Paterakis G (2011) An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions. Cytometry Part B - Clinical Cytometry 80 B:324–334. https://doi.org/10.1002/cyto.b.20608
doi: 10.1002/cyto.b.20608
Sahu S, Gupta P, Susheilia S, Gautam U, Dey P (2021) Application of multicolour flow cytometry in the detection of metastatic carcinoma in serous effusions: special emphasis in atypical cytology. Cytopathology 32:169–179. https://doi.org/10.1111/cyt.12922
doi: 10.1111/cyt.12922
pubmed: 33040400
Quirós-Caso C, Arias Fernández T, Fonseca-Mourelle A, Torres H, Fernández L, Moreno-Rodríguez M, Ariza-Prota MÁ, López-González FJ, Carvajal-Álvarez M, Alonso-Álvarez S, Moro-García MA, Colado E (2022) Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples. Cytometry Part B - Clinical Cytometry 1–11. https://doi.org/10.1002/cyto.b.22081
Risberg B, Davidson B, Dong HP, Nesland JM, Berner A (2000) Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings. J Clin Pathol 53:513–517. https://doi.org/10.1136/jcp.53.7.513
doi: 10.1136/jcp.53.7.513
pubmed: 10961174
pmcid: 1731234
Hooper C, Lee YCG, Maskell N, Pleural BTS (2010) Investigation of a unilateral pleural effusion in adults : british thoracic society pleural disease guideline 2010. 65. https://doi.org/10.1136/thx.2010.136978
Pinto D, Chandra A, Crothers BA, Kurtycz DFI, Schmitt F (2020) The international system for reporting serous fluid cytopathology—diagnostic categories and clinical management. J Am Soc Cytopathol 9:469–477. https://doi.org/10.1016/j.jasc.2020.05.015
doi: 10.1016/j.jasc.2020.05.015
pubmed: 32620534
Samper GJ, Herrera S, Estrella L, Marco J, Rafael B, Lapiedra A, Pinilla A (2017) Predicting Malignant and Paramalignant Pleural Effusions by combining Clinical, Radiological and Pleural Fluid Analytical Parameters. 653–660. https://doi.org/10.1007/s00408-017-0032-3
van Dongen JJM, Lhermitte L, Böttcher S, van der Almeida J, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26:1908–1975. https://doi.org/10.1038/leu.2012.120
doi: 10.1038/leu.2012.120
pubmed: 22552007
pmcid: 3437410
Orfao A, Matarraz S, Pérez-Andrés M, Almeida J, Teodosio C, Berkowska MA, van Dongen JJM (2019) Immunophenotypic dissection of normal hematopoiesis. J Immunol Methods 475:112684. https://doi.org/10.1016/j.jim.2019.112684
doi: 10.1016/j.jim.2019.112684
pubmed: 31676343
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B (2016) Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry part B -. Clin Cytometry 90:31–39. https://doi.org/10.1002/cyto.b.21228
doi: 10.1002/cyto.b.21228
pubmed: 25619868
Pillai V, Dorfman DM (2016) Flow cytometry of nonhematopoietic neoplasms. Acta Cytol 60:336–343. https://doi.org/10.1159/000448371
doi: 10.1159/000448371
pubmed: 27578265
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR (2018) Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 142:89–108. https://doi.org/10.5858/arpa.2017-0124-RA
doi: 10.5858/arpa.2017-0124-RA
pubmed: 28686500
del Díaz C, Saiz-Pardo Sanz M, Ortega Medina L, Fernández Aceñero MJ (2021) Ber-EP4 staining in effusion cytology: a potential source of false positives. Revista Esp de Patologia 54:114–122. https://doi.org/10.1016/j.patol.2020.04.005
doi: 10.1016/j.patol.2020.04.005
Attanoos RL, Griffin A, Gibbs AR (2003) The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231–238. https://doi.org/10.1046/j.1365-2559.2003.01686.x
doi: 10.1046/j.1365-2559.2003.01686.x
pubmed: 12940775
Maguire B, Whitaker D, Carrello S, Spagnolo D (1994) Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 10:130–134
doi: 10.1002/dc.2840100207
pubmed: 8187591
Salisbury T, Churg A (2021) CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations. Virchows Arch 479:1047–1050
doi: 10.1007/s00428-021-03077-7
pubmed: 33721119
Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T, Tsujimura T (2010) Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 23:1458–1466. https://doi.org/10.1038/modpathol.2010.134
doi: 10.1038/modpathol.2010.134
pubmed: 20657552
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Thompson JC, Fan R, Black T, Yu GH, Savitch SL, Chien A, Yee SS, Sen M, Hwang WT, Katz SI, Feldman M, Vachani A, Carpenter EL (2019) Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer 127:25–33. https://doi.org/10.1016/j.lungcan.2018.11.020
doi: 10.1016/j.lungcan.2018.11.020
pubmed: 30642547
Fuller MY, Thrall MJ (2016) Utility of flow cytometry analysis for pleural and peritoneal fluids. J Am Soc Cytopathol 5:339–344. https://doi.org/10.1016/j.jasc.2016.07.001
doi: 10.1016/j.jasc.2016.07.001
pubmed: 31042545
Plummer RM, Kelting S, Madan R, O’Neil M, Dennis K, Fan F (2020) Triaging of pleural effusion cytology specimens for ancillary flow cytometric analysis. J Am Soc Cytopathol 9:478–484. https://doi.org/10.1016/j.jasc.2020.07.131
doi: 10.1016/j.jasc.2020.07.131
pubmed: 32807715
Jie XX, Zhang XY, Xu CJ (2017) Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: mechanisms and clinical applications. Oncotarget 8:81558–81571. https://doi.org/10.18632/oncotarget.18277
doi: 10.18632/oncotarget.18277
pubmed: 29113414
pmcid: 5655309
Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 64:415–420. https://doi.org/10.1136/jcp.2011.090274
doi: 10.1136/jcp.2011.090274
pubmed: 21415054
Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, Bryne M, Asschenfeldt P, Risberg B (2002) Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 118:85–92. https://doi.org/10.1309/M877-QABM-D9GB-FJAX
doi: 10.1309/M877-QABM-D9GB-FJAX
pubmed: 12109861
Yoon JY, Nayyar R, Quest G, Pabedinskas D, Pal P, Tsao MS, Schwock J, Ko HM (2020) PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry. Lung Cancer 148:55–61. https://doi.org/10.1016/j.lungcan.2020.07.013
doi: 10.1016/j.lungcan.2020.07.013
pubmed: 32799091
De Sá Ferreira-Facio C, Botafogo V, Ferrão PM, Canellas MC, Milito CB, Romano S, Lopes DV, Teixeira LC, Oliveira E, Bruno-Riscarolli E, Mello FV, Siqueira PFR, Moura P, Macedo FN, Forny DN, Simião L, Pureza AL, Poirot Land MG, Pedreira CE, Van Dongen JJM, Orfao A, Da Costa ES (2021) Flow cytometry immunophenotyping for diagnostic orientation and classification of pediatric cancer based on the euroflow solid tumor orientation tube (stot). Cancers 13. https://doi.org/10.3390/cancers13194945